Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €13.15 EUR
Change Today -0.08 / -0.60%
Volume 254.0K
IPH On Other Exchanges
EN Paris
As of 11:35 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

innate pharma sa (IPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - €17.85
52 Week Low
10/16/14 - €5.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INNATE PHARMA SA (IPH)

Related News

No related news articles were found.

innate pharma sa (IPH) Related Businessweek News

No Related Businessweek News Found

innate pharma sa (IPH) Details

Innate Pharma S.A., a biopharmaceutical company, engages in the research and development of pharmaceutical product primarily immunotherapy drugs for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it engages in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. The company has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

110 Employees
Last Reported Date: 09/17/15
Founded in 1999

innate pharma sa (IPH) Top Compensated Officers

Co-Founder, Chairman of Executive Board and C...
Total Annual Compensation: €352.3K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: --
Member of Executive Board, Senior Advisor Fin...
Total Annual Compensation: €265.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: €208.1K
Compensation as of Fiscal Year 2014.

innate pharma sa (IPH) Key Developments

Innate Pharma SA Announces the Opening of the Phase I/II Trial of IPH2201

Innate Pharma SA announced the opening of the Phase I/II trial of IPH2201, a NKG2A checkpoint inhibitor, tested in combination with ibrutinib in patients with relapsed or refractory Chronic Lymphocytic Leukemia. This trial, which will include up to 45 patients, is multicentric and will be performed in the United States.

Innate Pharma S.A. Announces First Patient Treated in Phase I/II Trial with IPH2201 in Ovarian Cancer

Innate Pharma SA announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint inhibitor, as a single agent in platinum resistant or sensitive patients with high grade ovarian cancer. The trial is sponsored by NCIC Clinical Trials Group and conducted in Canada. Thirty-eight (38) patients are planned to be enrolled. This is the second out of four trials announced by Innate Pharma, included in the frame of the global co-development and commercialization agreement signed with AstraZeneca for IPH2201 in April 2015. The first trial (IPH2201-201) is an open label Phase II trial testing IPH2201 as a single agent in a pre-operative setting of squamous cell carcinoma of the oral cavity (OCSCC). The first patient was treated at the Charité Comprehensive Cancer Center (CCCC), Berlin, Germany, in December 2014. This Phase I/II trial is an open-label, multicentre, dose ranging study of single agent IPH2201 administered i.v. every 2 weeks in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma of ovarian, fallopian tube or peritoneal origin. In the first part of the study, a total of 18 patients (6/dose level) will be randomized to one of 3 dose levels: 1 mg/kg, 4 mg/kg and 10 mg/kg. The recommended Phase II dose (RP2D) will be determined based on toxicity, pharmacokinetics and pharmacodynamics data. Thereafter, a total of 20 patients (10/cohort) will be registered to two cohorts (platinum sensitive or resistant) and will receive IPH2201 at the RP2D. The objectives of the second part of the trial are to perform a preliminary assessment of the efficacy (measured by the response rate) of IPH2201, as well as of its safety, pharmacokinetics, pharmacodynamics and immunogenicity. Many patients with ovarian cancer suffer from ascites, which will allow documentation of the pharmacological effects of IPH2201.

Innate Pharma S.A. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2015

Innate Pharma S.A. reported consolidated earnings results for the six months ended June 30, 2015. For the six months, revenue from collaboration and licensing agreements was EUR 3,092,000 against EUR 1,027,000 a year ago. Operating loss was EUR 9,046,000 against EUR 9,063,000 a year ago. Net loss before tax was EUR 6,974,000 against EUR 9,039,000 a year ago. Net loss was EUR 6,974,000 against EUR 9,039,000 a year ago. Diluted net loss per share attributable to the equity holders of the company was EUR 0.13 against EUR 0.19 a year ago. Net cash generated from operating activities was EUR 208,590,000 against net cash used in operating activities of EUR 8,759,000 a year ago. Acquisition of property and equipment was EUR 233,000 against EUR 230,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPH:FP €13.15 EUR -0.08

IPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation IPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.4x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNATE PHARMA SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at